Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones

Item
http://www.wikidata.org/entity/Q27851527
Dinosaurs and ancient civilizations: reflections on the treatment of cancerCIViC databaseLung cancer in never smokersAllele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutationKRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing.Frequent heterogeneous missense mutations of GGAP2 in prostate cancer: implications for tumor biology, clonality and mutation analysisTemporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse alleleCommon and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma.Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations.The interconnectedness of cancer cell signaling.Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis.Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Ocular metastasis of lung adenocarcinoma with ELM4-ALK translocation: A case report with a review of the literature.Low-frequency KRAS mutations are prevalent in lung adenocarcinomasKRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatmentsThe War on Cancer rages on.EGFR mutations and the terminal respiratory unit.Biomarkers in bronchopulmonary cancer.Molecular testing in lung cancer: the time is now.New and potential clinical applications of KRAS as a cancer biomarker.Comparison of EGFR mutation detection between the tissue and cytology using direct sequencing, pyrosequencing and peptide nucleic acid clamping in lung adenocarcinoma: Korean multicentre study.Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma.Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging.Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model.Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.[Molecular diagnostics in lung carcinoma for therapy stratification].[EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance].The molecular landscape of synchronous colorectal cancer reveals genetic heterogeneity.FGFR1 Amplification in Squamous Cell Carcinoma of the Lung with Correlation of Primary and Metastatic Tumor Status.LncRNA expression profiles of EGFR exon 19 deletions in lung adenocarcinoma ascertained by using microarray analysis.Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells.A seven-long noncoding RNA signature predicts overall survival for patients with early stage non-small cell lung cancerPrognostic value of and in resected non-small cell lung cancer: a systematic review and meta-analysis
P2860
Q24628746-C6D71095-0BA9-4193-ABC0-6A9B18F025EAQ27612411-F750C9E3-30D6-40DF-9F28-B5F6EA49B3D6Q28386853-F914A373-2C71-4084-A035-BB8270B8657CQ28730199-87C62D2E-EB60-41EB-8A44-ED57D20F9C06Q33634165-C0B0458A-7A9C-4539-8B26-2C077C5DBDE5Q34184661-34AF3878-B518-4261-B440-6D3E48C4C92FQ34273969-2BDFB6B3-D33F-4A4B-9C50-CE93D34E2BC3Q34906960-40F0FFD6-1A9F-4AF9-84B1-27F956310DD3Q35107404-8754E68D-9F2B-4387-BB0C-DB8289FDE568Q35642677-D3E4FE14-8C15-461F-9EF0-E172E35EEFFFQ35669733-062F5342-F574-4170-B5F1-4DF22003CC86Q35824117-DD94A737-577E-4363-A5F1-81D09794CACBQ35828688-3E05A568-B7C8-4009-947E-4F68E768C927Q36946809-6EACE02F-D4DF-4C38-8FFA-B02263ECB3F2Q37163460-01A101FF-E45F-4B79-899E-7AB7A301B540Q37375834-56944DAB-43B0-47CF-A3B4-FE09710528E3Q37423355-52B057F5-F7AA-4897-A0A4-AD9167BAC0F1Q37478602-3004286C-B379-4D43-9EF8-AEC4506EF24AQ37687922-438AB4A4-2F66-48A1-A29A-DDC3BB223887Q37692666-D2E1C28A-FCC6-4A32-A049-84EC3653B0F9Q37771888-D6B5C91D-E669-4804-806A-26817B3E99C5Q38089885-A9A33DA7-5C32-44FA-9136-EC76868687C1Q38386062-4D742619-00FE-4F86-83DB-B3441BDB5E03Q38526025-C13DDC61-35EF-4C03-8909-92102F42BC7DQ38734002-EEBEB7F7-1B69-446A-BACD-F34F6242DD58Q38853649-697BC2CB-DE24-4164-BCB9-EA5FF42C70B1Q39705991-5EE95D26-89C5-4B33-9CEE-BF836DA64917Q41377253-BB9EB296-9B57-43BE-BAA7-696968E9255DQ42204869-06E1FC58-6C5D-4F98-B55E-B3F15DB66A68Q43226909-94B89F32-D6CC-4DD4-A051-6B4AF05251E3Q49958940-3B6C15AC-89FC-4A1A-A9F0-D34A5FEC7F93Q53177096-2219C26A-0760-4847-835D-14C9907243D8Q53227868-1ECD5D00-E910-4724-BD1A-B6626AB370A1Q54196176-9BD8577E-98CC-41C8-89B3-FBB483175A2CQ54271301-C084301A-3E20-4CD3-A17D-D08322A6EC65Q58749147-35E2CE97-4263-4CA7-AD3A-3DA6ED893DD4Q58754535-5E3BC5EE-14AC-44DD-B583-538EDB0BE926
P2860

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones

Item
http://www.wikidata.org/entity/Q27851527
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Clinical implications of KRAS ...... for mutations in minor clones
@ast
Clinical implications of KRAS ...... for mutations in minor clones
@en
Clinical implications of KRAS ...... for mutations in minor clones.
@nl
type
label
Clinical implications of KRAS ...... for mutations in minor clones
@ast
Clinical implications of KRAS ...... for mutations in minor clones
@en
Clinical implications of KRAS ...... for mutations in minor clones.
@nl
prefLabel
Clinical implications of KRAS ...... for mutations in minor clones
@ast
Clinical implications of KRAS ...... for mutations in minor clones
@en
Clinical implications of KRAS ...... for mutations in minor clones.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Clinical implications of KRAS ...... for mutations in minor clones
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932